Combination therapy with @entity2816 plus @entity619 for newly diagnosed XXXX .

@entity1 @entity632 @entity788 @entity137 @entity1910 @entity1353 @entity2816 @entity1151 @entity1582 @entity619 @entity1150 @entity281 @entity1891 @entity1142 @entity204
PURPOSE: @entity1582 is a malignancy of plasma cells and is characterized by increased marrow angiogenesis. @entity2816 , an agent with antiangiogenic properties, is effective in relapsed @entity1582 . We report the results of a study combining @entity2816 and @entity619 as initial therapy for @entity1582 . @entity1 AND METHODS: Fifty @entity1 with newly diagnosed @entity1582 were studied. @entity2816 was given at a dose of 200 mg/d orally. @entity619 was given at a dose of 40 mg/d orally on days 1 to 4, 9 to 12, and 17 to 20 (odd cycles) and 40 mg/d on days 1 to 4 (even cycles), repeated monthly. RESULTS: Of all 50 @entity1 , a confirmed response was seen in 32 @entity1 yielding a response rate of 64% (95% confidence interval, 49% to 77%). Thirty-one @entity1 (62%) proceeded to stem-cell collection after four cycles of therapy including 26 who underwent stem-cell transplantation and five who chose stem-cell cryopreservation. Major grade 3 or 4 @entity137 were observed in 16 @entity1 (32%), and the most frequent were @entity1150 (six @entity1 ), @entity1142 (four @entity1 ), @entity1910 (three @entity1 ), and @entity1353 (two @entity1 ). Three @entity204 occurred during active therapy because of a @entity788 , @entity1151 , and @entity281 . CONCLUSION: We conclude that the combination of @entity2816 plus @entity619 is a feasible and active regimen in the treatment of @entity1582 . It merits further study as an oral alternative to infusional chemotherapy with @entity1891 , @entity632 , and @entity619 and other intravenous regimens currently used as pretransplantation induction therapy for @entity1582 .
